Communicators

are winners!

Top News

15.03.2024
Highlights: -          Dosing of 4 clinical subjects complete in Phase I/II UTI/Urosepsis fast infusion I.V. study of RECCE® 327 at 3,000mg over 20 minutes-          Data received from this cohort will support preparations for a Phase II UTI/Urosepsis efficacy clinical trial  Sydney Australia, 15 March 2024: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (the Company), the Company developing a New Class of Synthetic Anti-Infectives, is pleased to report it has successfully completed dosing of its latest cohort in its Phase I/II ... [ more ]